Form D Explorer
Aegle Therapeutics Corp · CIK 1797825

Report a data issueCitable research briefCompare issuerPrivate research collection

Aegle Therapeutics Corp

CIK 1797825 · Corporation · Inc. DELAWARE · WOBURN, Massachusetts · Biotechnology

These Form D notices describe private placements reported to the SEC. Read Form D/A amendments alongside the original disclosures.

Filings
2
Original notices
2
Amendments
0
Activity
Mar 3, 2026
through Aug 28, 2026

Figures are issuer-reported and describe stored filings. Data coverage and methodology.

Differences between reported disclosures

Same issuer CIK; offering identity has not been established. Differences are arithmetic comparisons between disclosures, not additional capital raised, new investors or confirmed amendments to the same offering.

Unavailable values are shown as a dash; reported zero remains zero.
FieldMar 3, 2026 · DAug 28, 2026 · DLater minus earlier
Reported offering amount$700,000$2,277,698$1,577,698
Reported amount sold$455,695$2,277,698$1,822,003
Reported investor count—17—
Reported minimum investment$0$0$0

Earlier SEC source: 0001231919-26-000232 · Later SEC source: 0001797825-26-000007

Choose filings to compare · Research this issuer step by step

Latest available filing snapshot: how to read these fields

Form D · Aug 28, 2026

Reported offering amount
$2,277,698
Reported exemptions
Rule 506(b)
Reported amount sold
$2,277,698

This is one filing's disclosure, not the issuer's lifetime fundraising or current offering status.

Form D filings (2)